For immediate release |
2 January 2013 |
Futura Medical plc
("Futura" or "the Company")
Remuneration of Non-Executive Directors
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces the issue today of 33,865 shares in respect of the 2012 remuneration of its Non-Executive Directors.
In accordance with the announcement of 6 January 2012, Non-Executive Directors receive approximately 30 per cent of their remuneration in the Company's ordinary shares. For 2012 these were issued at 84.10 pence per share, being the average closing mid-price of the 10 trading days prior to the 6 January 2012. The 33,865 new ordinary shares shall rank pari passu with the existing issued ordinary shares of the Company and have been issued as follows:
Director |
Number of ordinary shares issued for 2012 remuneration |
Total number of ordinary shares held |
Percentage of the Company's issued share capital |
John Clarke |
20,405 |
20,405 |
0.03% |
Jonathan Freeman |
6,802 |
6,802 |
0.01% |
Lisa Arnold |
6,658 |
6,658 |
0.01% |
Application has been made to the London Stock Exchange and it is anticipated that trading of the new ordinary shares will commence on AIM at 8:00am on 8 January 2013.
For the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 77,447,946 ordinary shares of 0.2p each, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 77,447,946.
The above figure of 77,447,946 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
The shares element of the 2013 year's Non-Executive Directors' remuneration will be awarded at 58.15 pence per share, being the average closing mid-price of the last 10 trading days of 2012. The Non-Executive Directors will receive the shares at the end of the 2013 financial year.
Full details of Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.
For any further information please contact:
Futura Medical plc |
+ 44 (0) 1483 685 670 |
James Barder, Chief Executive Officer Mail to: [email protected] |
www.futuramedical.com |
|
|
Nomura Code Securities Limited |
+ 44 (0) 20 7776 1200 |
Phil Walker / Giles Balleny |
|
|
|
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
|
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
